Nuvalent, Inc.
- Open
- 123.52
- Day high
- 123.56
- Day low
- 123.43
- Prev close
- 123.51
- Volume
- 991K
- Mkt cap
- $9.8B
- P/E (TTM)
- —
- EPS (TTM)
- —
- P/B
- 8.3
- P/S
- —
- Yield
- —
- Per share
- —
- ▼Insiders net selling -$16.2M over the last 3 months (0 open-market buys, 35 sales)
- 🏛Institutions accumulating (13F)
Nuvalent, Inc. (NUVL) is a Healthcare company listed on NASDAQ. The stock is up 58% over the past year. Over the trailing 3 months, insiders filed 0 open-market buys and 35 sales (SEC Form 4). Drillr has 2 published research articles covering NUVL.
Nuvalent, Inc. (NUVL) financials & analyst ratings
Fundamentals (TTM)
Analyst consensus · 10 analysts
Source: exchange market data + company filings. Figures are trailing-twelve-month or as most recently reported. For informational purposes only — not investment advice.
NUVL earnings date, history & EPS estimates
| Report date | EPS est | EPS actual | Surprise | Revenue | Rev. surprise |
|---|---|---|---|---|---|
| May 7, 2026 | $-1.35 | $-1.39 | -3.0% | — | — |
| Oct 30, 2025 | $-1.39 | $-1.70 | -22.3% | — | — |
| Aug 7, 2025 | $-1.27 | $-1.31 | -3.1% | — | — |
| May 8, 2025 | $-1.14 | $-1.18 | -3.5% | — | — |
| Feb 27, 2025 | $-1.04 | $-1.05 | -1.0% | — | — |
| Aug 8, 2024 | $-0.76 | $-0.88 | -15.8% | — | — |
| May 9, 2024 | $-0.67 | $-0.69 | -3.0% | — | — |
| Feb 27, 2024 | $-0.59 | $-0.62 | -5.1% | — | — |
| Nov 14, 2023 | $-0.59 | $-0.59 | +0.0% | — | — |
| Aug 10, 2023 | $-0.53 | $-0.51 | +3.8% | — | — |
| May 11, 2023 | $-0.51 | $-0.44 | +13.7% | — | — |
| Mar 16, 2023 | $-0.43 | $-0.49 | -14.0% | — | — |
NUVL insider trading activity (SEC Form 4)
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| Jun 18, 2026 | Meyers Michael L.director | Grant | 3,444 | — |
| Jun 18, 2026 | Wheeler Camerondirector | Grant | 3,444 | — |
| Jun 18, 2026 | Squarer Rondirector | Grant | 3,444 | — |
| Jun 18, 2026 | Flynn James Edirector, 10 percent owner, other: Director by Deputization | Grant | 3,444 | — |
| Jun 18, 2026 | Protopapas Annadirector | Grant | 3,444 | — |
| Jun 18, 2026 | Oliger Christy J.director | Grant | 3,444 | — |
| Jun 18, 2026 | Bogle Grant C.director | Grant | 3,444 | — |
| Jun 18, 2026 | Srivastava Sapnadirector | Grant | 3,444 | — |
| Jun 11, 2026 | Noci Darleneofficer: Chief Development Officer | Option | 9,315 | $18.93 |
| Jun 11, 2026 | Noci Darleneofficer: Chief Development Officer | Sell | 20,000 | $122.81 |
| Jun 11, 2026 | Noci Darleneofficer: Chief Development Officer | Option | 10,000 | $1.08 |
| Jun 11, 2026 | Noci Darleneofficer: Chief Development Officer | Option | 685 | $6.89 |
| Jun 10, 2026 | Porter James Richarddirector, officer: President and CEO | Sell | 12,495 | $87.97 |
| Jun 10, 2026 | Porter James Richarddirector, officer: President and CEO | Sell | 14,469 | $88.79 |
| Jun 10, 2026 | Porter James Richarddirector, officer: President and CEO | Sell | 3,036 | $89.63 |
Source: NUVL SEC Form 4 filings, latest Jun 18, 2026. For informational purposes only — not investment advice.
See the full NUVL insider & 13F page →NUVL research & analysis
GSK Stock: How the $9B Nuvalent Deal Reshapes Pipeline
The $9B Nuvalent deal lifts GSK net leverage to roughly 2.7x EBITDA but fills two oncology pipeline gaps. Risk-adjusted NPV at $10-12B supports the price.
GSKNUVL Stock: Why GSK's $9B Takeover Talks Matter
NUVL at $88.49 implies 25-35% probability the rumored $130-135 GSK deal closes. ROS1 and ALK CNS programs fit GSK pipeline gaps.
GSK
Nuvalent, Inc. company profile
Overview
Nuvalent, Inc. (NASDAQ:NUVL) is a clinical-stage biopharmaceutical company founded in 2017 and headquartered in Cambridge, Massachusetts. The company went public in July 2021 and focuses on developing precision oncology therapies for cancer patients. Nuvalent specializes in creating targeted inhibitors for specific genetic mutations that drive certain types of cancer, particularly lung cancers with ROS1 and ALK gene fusions.
Business
Nuvalent operates in the precision oncology sector of biotechnology, developing targeted cancer therapies that address specific genetic mutations. The company's approach focuses on creating drugs that can overcome resistance mechanisms that often develop with existing cancer treatments. The company's pipeline centers around two main product candidates. NVL-520 is a brain-penetrant ROS1-selective inhibitor currently in Phase I clinical development. ROS1 is a gene that, when fused with other genes, can drive certain lung cancers. Existing ROS1 inhibitors often lose effectiveness as cancer cells develop resistance mutations, and NVL-520 is designed to remain active even when these resistance mutations emerge. The "brain-penetrant" characteristic is crucial because many cancer drugs cannot effectively cross the blood-brain barrier to treat brain metastases. NVL-655 is the company's second lead candidate, a brain-penetrant ALK-selective inhibitor in Phase I/II clinical trials. ALK (anaplastic lymphoma kinase) is another gene that drives certain cancers when fused with other genes. Like ROS1 inhibitors, existing ALK inhibitors face challenges with treatment resistance, central nervous system side effects, and limited brain penetration. NVL-655 aims to address these limitations while maintaining selectivity for the ALK target. Both programs represent Nuvalent's core strategy of developing next-generation kinase inhibitors that can overcome the clinical limitations of current approved therapies, particularly resistance development and inadequate brain penetration.
Revenue model
As a clinical-stage biopharmaceutical company, Nuvalent currently generates no revenue from product sales, as both of its lead candidates are still in clinical development. The company operates on a research and development model funded primarily through equity financing and cash reserves from its initial public offering and subsequent fundraising activities. The company's future revenue model will likely depend on several potential pathways. Upon successful clinical development and regulatory approval, Nuvalent could generate revenue through direct product sales, particularly in the precision oncology market where targeted therapies often command premium pricing due to their specificity and clinical benefits. Alternatively, the company might pursue partnership or licensing agreements with larger pharmaceutical companies, which could provide upfront payments, milestone payments during development, and royalties on future sales. Several factors could significantly impact Nuvalent's future profitability and margins. The success of clinical trials represents the primary determinant of value, as failure in Phase II or Phase III studies could eliminate the commercial potential entirely. The competitive landscape in ROS1 and ALK inhibitors continues to evolve, with multiple companies developing next-generation inhibitors, which could affect market share and pricing power. Regulatory approval timelines and requirements will influence development costs and time to market. Additionally, the size of the addressable patient population for ROS1 and ALK-driven cancers, while significant, represents a subset of the broader lung cancer market, which could limit peak sales potential compared to broader-indication therapies.
Competitive moat
Nuvalent's competitive moat is relatively narrow and primarily based on its scientific expertise in kinase inhibitor design and its specific focus on brain-penetrant, selective inhibitors. The company's leadership team has significant experience in precision oncology drug development, and their approach to designing inhibitors that maintain activity against resistance mutations represents a meaningful technical advantage. However, the biotechnology industry offers limited sustainable competitive advantages during the clinical development phase. Patent protection provides some exclusivity, but the fundamental challenge is that multiple companies are pursuing similar next-generation approaches to ROS1 and ALK inhibition. Companies like Pfizer, Roche, and other biotechnology firms have competing programs targeting the same genetic drivers of cancer. The company's brain-penetrant design represents a potential differentiating factor, as central nervous system penetration remains a significant clinical challenge for many cancer therapies. If Nuvalent's compounds demonstrate superior brain penetration and efficacy in treating brain metastases compared to competitors, this could provide a meaningful clinical advantage. The ultimate competitive moat will depend on clinical trial results, regulatory approval timing, and the company's ability to demonstrate superior efficacy and safety profiles compared to existing and emerging competitors. In precision oncology, first-mover advantage and strong clinical data can create significant market position, but these advantages can be eroded by superior competing therapies.
Risks & safety
Nuvalent maintains a relatively strong financial position for a clinical-stage biotechnology company, though it faces the inherent risks of pre-revenue drug development. • Cash position: The company holds approximately $121 million in cash and short-term investments as of Q1 2025, down from $146 million in Q4 2024, indicating ongoing cash consumption for operations. • Burn rate: Operating cash flow was negative $55 million in Q1 2025 and negative $185 million for full year 2024, suggesting a quarterly burn rate of approximately $45-60 million. • Runway: Based on current burn rates, the company has roughly 2-3 years of cash runway, which may require additional financing before potential product commercialization. • Debt position: The company maintains zero debt, eliminating solvency risk from debt obligations. • Liquidity ratios: Current ratio of 14.5x and quick ratio of 14.5x indicate strong short-term liquidity position. • Valuation metrics: Trading at 5.0x price-to-book ratio, which is elevated for a pre-revenue company but not uncommon in biotechnology. • Other considerations: The company's valuation and future prospects are entirely dependent on clinical trial outcomes, creating binary risk scenarios typical of clinical-stage biotechnology investments.
Recent development
Based on the available financial data, Nuvalent has been advancing its clinical development programs consistently over the past few years. The company has maintained focus on its two lead programs, NVL-520 and NVL-655, progressing both through early-stage clinical trials. The company's development strategy has emphasized the brain-penetrant characteristics of both compounds, addressing a significant unmet medical need in treating central nervous system metastases in ROS1 and ALK-driven cancers. This focus on brain penetration represents a key differentiating factor in the competitive landscape of kinase inhibitors. Financial management has been a key focus, with the company managing its cash burn while advancing multiple clinical programs. The increase in operating expenses from $99 million in 2023 to $185 million in 2024 reflects the intensification of clinical development activities as both programs advance through clinical trials. The company has maintained its clinical-stage focus without pursuing partnership agreements or out-licensing arrangements, suggesting confidence in its ability to advance programs independently through at least early-stage development. This approach preserves full commercial rights but requires continued independent funding of development activities.
NUVL company profile · for informational purposes only — not investment advice.
Track NUVL with Drillr
SEC filings, earnings calls, insider activity, alt-data signals — all queryable through Drillr's AI terminal and MCP API.
Try Drillr for free